辉瑞以100亿美元击败诺和诺德,成功收购减肥药初创公司Metsera,溢价高达159%。凭借FTC批准,辉瑞获得战略突破,布局千亿美元减肥药市场,抢占下一代疗效更强、副作用更低的新药赛道。制药巨头们的竞争风暴正迅速席卷全球医药产业。辉瑞公司在一场与诺和诺德的激烈竞购战后,最终以100亿美元的价格成功收购了减肥药初创公司Metsera Inc.。根据Metsera周五晚间的声明,辉瑞将以每股最高...
Source Link辉瑞以100亿美元击败诺和诺德,成功收购减肥药初创公司Metsera,溢价高达159%。凭借FTC批准,辉瑞获得战略突破,布局千亿美元减肥药市场,抢占下一代疗效更强、副作用更低的新药赛道。制药巨头们的竞争风暴正迅速席卷全球医药产业。辉瑞公司在一场与诺和诺德的激烈竞购战后,最终以100亿美元的价格成功收购了减肥药初创公司Metsera Inc.。根据Metsera周五晚间的声明,辉瑞将以每股最高...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.